The Interpretation of Guideline of Appropriate Use of Tigecycline_Chinese Journal of Evidence-Based Medicine

Authors：

 DONGWei , XIEXiao-qi ,  KANGYan

Department of Intensive Care Unit, West China Hospital, Sichuan University, Chengdu 610041, China;

Corresponding author：

KANGYan, Email: kang_yan_123@163.com

Keywords：

Tigecycline; Infection; Drug resistant bacteria; Clinical practice guideline

DOI：

10.7507/1672-2531.20160007

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： DONGWei, XIEXiao-qi, KANGYan. The Interpretation of Guideline of Appropriate Use of Tigecycline. Chinese Journal of Evidence-Based Medicine, 2016, 16(1): 30-32. doi: 10.7507/1672-2531.20160007 Copy

1.	Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t.butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother, 1999, 43(4): 738-744.
2.	Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis, 2010, 50(2): 133-164.
3.	Hawser SP, Bouchillon SK, Hackel M, et al. Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010. Int J Antimicrob Agents, 2012, 39(6): 490-495.
4.	Brink AJ, Bizos D, Boffard KD, et al. Guideline: appropriate use of tigecycline. S Afr Med J, 2010, 100(6 Pt 2): 388-394.
5.	Peterson LR. A review of tigecycline: the first glycylcyclines. Int J Antimicrob Agents, 2008, 32(Suppl 4): S215-222.
6.	Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents, 2009, 34(1): 8, e1-e9.
7.	Ellis-Grosse EJ, Babinchak T, Dartois N, et al. Tigecycline 300 cSSSI study group, Tigecycline 305 cSSSI study group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis, 2005, 41 Suppl 5: S341-S353.
8.	Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis, 2010, 68(2): 140-151.
9.	Vasilev K, Reshedko G, Orasan R, et al. A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gramnegative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother, 2008, 62 Suppl 1: i29-i40.
10.	Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother, 2008, 62 Suppl 1: i17-i28.
11.	Gardiner D, Dukart G, Cooper C, et al. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteraemia: pooled results from 8 phase III clinical trials. Clin Infect Dis, 2010, 50(2): 229-238.
12.	Ramirez J, Dartois N, Gandjini H, et al. Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia. Antimicrob Agents Chemother, 2013, 57(4): 1756-1762.
13.	Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis, 2008, 61(3): 329-338.
14.	Solomkin JS, Mazuski JE, Bradley, JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis, 2010, 50(2): 133-164.
15.	Farthmann EH, Schöffel U. Epidemiology and pathophysiology of intraabdominal infections (IAI). Infection, 1998, 26(5): 329-334.
16.	LaRoche M, Harding G. Primary and secondary peritonitis: an update. Eur J Clin Microbiol Infect Dis, 1998, 17(8): 542-550.
17.	Malangoni MA. Evaluation and management of tertiary peritonitis. Am Surg, 2000, 66(2): 157-161.
18.	Barie PS. Management of complicated intra-abdominal infections. J Chemother, 1999, 11(6): 464-477.
19.	Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis, 2004, 39(7): 885-910.

1. Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t.butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother, 1999, 43(4): 738-744.
2. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis, 2010, 50(2): 133-164.
3. Hawser SP, Bouchillon SK, Hackel M, et al. Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010. Int J Antimicrob Agents, 2012, 39(6): 490-495.
4. Brink AJ, Bizos D, Boffard KD, et al. Guideline: appropriate use of tigecycline. S Afr Med J, 2010, 100(6 Pt 2): 388-394.
5. Peterson LR. A review of tigecycline: the first glycylcyclines. Int J Antimicrob Agents, 2008, 32(Suppl 4): S215-222.
6. Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents, 2009, 34(1): 8, e1-e9.
7. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. Tigecycline 300 cSSSI study group, Tigecycline 305 cSSSI study group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis, 2005, 41 Suppl 5: S341-S353.
8. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis, 2010, 68(2): 140-151.
9. Vasilev K, Reshedko G, Orasan R, et al. A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gramnegative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother, 2008, 62 Suppl 1: i29-i40.
10. Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother, 2008, 62 Suppl 1: i17-i28.
11. Gardiner D, Dukart G, Cooper C, et al. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteraemia: pooled results from 8 phase III clinical trials. Clin Infect Dis, 2010, 50(2): 229-238.
12. Ramirez J, Dartois N, Gandjini H, et al. Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia. Antimicrob Agents Chemother, 2013, 57(4): 1756-1762.
13. Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis, 2008, 61(3): 329-338.
14. Solomkin JS, Mazuski JE, Bradley, JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis, 2010, 50(2): 133-164.
15. Farthmann EH, Schöffel U. Epidemiology and pathophysiology of intraabdominal infections (IAI). Infection, 1998, 26(5): 329-334.
16. LaRoche M, Harding G. Primary and secondary peritonitis: an update. Eur J Clin Microbiol Infect Dis, 1998, 17(8): 542-550.
17. Malangoni MA. Evaluation and management of tertiary peritonitis. Am Surg, 2000, 66(2): 157-161.
18. Barie PS. Management of complicated intra-abdominal infections. J Chemother, 1999, 11(6): 464-477.
19. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis, 2004, 39(7): 885-910.

Chinese Journal of Evidence-Based Medicine

The Interpretation of Guideline of Appropriate Use of Tigecycline

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content